An AI model may help identify patients with myelofibrosis at high risk of early death after transplant, according to an ...

before transplantation and the overall survival (OS) of patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median follow-up time among the patients was 19.7 months ...

shared insights with CURE on the development of a machine learning model aimed at improving transplant risk assessment for patients with myelofibrosis. Mosquera explained the importance of using ...

Although there are several therapies available to treat myelofibrosis, the only curative option remains allogeneic-hematopoietic cell transplantation (allo-HCT), when healthy stem cells from a ...

Although there are several therapies available to treat myelofibrosis, the only curative option remains allogeneic hematopoietic cell transplantation (allo-HCT), when healthy stem cells from a ...

Although there are several therapies available to treat myelofibrosis, the only curative option remains allogeneic-hematopoietic cell transplantation (allo-HCT), when healthy stem cells from a ...

Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At 2 years and 4 years post-transplant, relapse-free survival rates were 94% and 89% ...

Hematopoietic stem cell transplantation (HSCT) plays a significant therapeutic role in treating these patients. Theodore B. Moore, MD, Director, UCLA Pediatric Bone Marrow Transplant Program ...

in allogeneic hematopoietic stem cell transplantation (allo-HSCT), highlighting the role of the recipient's circadian rhythms. The team was led by Prof. Zhan Cheng from the University of Science ...

Folashade Otegbeye is a clinical researcher who specializes in blood stem cell transplantation for blood cancers and other diseases of blood and marrow. In her lab, she studies the immunology of ...